Search

Your search keyword '"Schär S"' showing total 155 results

Search Constraints

Start Over You searched for: Author "Schär S" Remove constraint Author: "Schär S"
155 results on '"Schär S"'

Search Results

2. Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

3. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study

4. SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY

5. P268 Impact of the 2020 COVID-19 lockdown in Switzerland on physical activity in patients with early breast cancer under aromatase-inhibitor therapy. A subanalysis of the SAKK 95/17 WISE trial

7. Effect of a 24 week home-based walking program on the incidence of aromatase inhibitor induced musculoskeletal pain: The WISE prospective, randomized, multicenter trial [SAKK 95/17]

9. 1223P Sex specific efficacy and safety outcomes in operable stage III non-small cell lung cancer (NSCLC): Pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

12. Corrigendum to ‘Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials’

14. Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

15. Einbezug ganzheitlicher Behandlungs- und Pflegestrategien in die Patientenversorgung: Vermittlung eines Kommunikationsmodells zur ���Spiritual Care��� mittels blended learning ��� ein Pilotprojekt

17. Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]

24. Über’s Sterben sprechen: Das Wesentliche der Kommunikation über den nahenden Tod aus unterschiedlichen Perspektiven

27. SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK

29. Fokusgruppenstudie zur Validierung eines 'spiritual-care' Gesprächsmodells

30. Advantages, disadvantages and barriers on changing continuous professional development (CPD) for registered nurses in Switzerland. Perspectives of experts in nursing education and nursing management: First results of a mixed methods study

31. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations

36. Contouring Quality and Adherence to EORTC-based Protocol Guidelines in the Randomized Phase III SAKK 09/10 Trial for Postoperative Prostate Cancer Radiotherapy: Implications for Treatment Quality and Future Clinical Trials

41. SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS

44. Evaluating a framework of theoretical hypotheses for animation learning

45. Atomic structure of alkali halide surfaces

47. SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN PATIENTS WITH DLBCL. A MULTICENTER, OPEN‐LABEL, PHASE II TRIAL.

49. Année politique suisse 2010

50. Evaluation eines neuen Mentoring-Programms für Medizinstudierende in der hausärztlichen Grundversorgung: Erfahrungen von Studierenden und Lehrärzten

Catalog

Books, media, physical & digital resources